09 October 2019 | News
Dr. He was a former Global Head of Computational, Biopharmaceutics and Translational PK/PD at Novartis
Ascletis Pharma, an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases has announced that Dr. Handan He joins Ascletis as Chief Scientific Officer, reporting to Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis.
Dr. He was a former Global Head of Computational, Biopharmaceutics and Translational PK/PD at Novartis Pharmaceutical Corporation, New Jersey, USA. She managed scientific teams across Novartis global sites in USA and Switzerland. Her main responsibilities included in silico ADME predictions, human PK/PD projections, translational PK/PD, in vitro and in vivo correlations, and clinical Physiologically Based Pharmacokinetic modeling for drug absorption, drug interaction, organ impairment and pediatrics.
Dr. He joined Novartis, New Jersey in 1997. Over her 22 years tenure at Novartis, Dr. He authored more than 30 INDs and 3 NDAs (Galvus, Indacaterol and Midostaurin), and supported all disease areas in both preclinical and clinical stages at Novartis. She conducted 15 due-diligence evaluation projects (phase I through phase III) to help strengthen the Novartis pipeline.
Dr. Wu added, "I am excited to have Dr. He on board. Dr. He's scientific experience and track record will bring great value to our R&D organization.”
"Ascletis' R&D strategy has been successful since its founding. I look forward to working with Dr. Wu and the team to discover and develop first-in-class medicines”, added Dr He
Dr. He was a recipient of the 2009 Outstanding 50 Asian Americans in Business Award. This recognition is the most prestigious Asian American business award in the U.S. to honor individuals for outstanding leadership, vision and accomplishments. In 2008, Dr.
Dr. He served as the 20th President of Sino-American Pharmaceutical Professionals Association (SAPA), an organization of over 4000 pharmaceutical scientists.